CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.93 and traded as high as $5.66. CASI Pharmaceuticals shares last traded at $5.49, with a volume of 10,524 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of CASI Pharmaceuticals in a research report on Saturday, August 3rd. They set a “hold” rating on the stock.
Get Our Latest Research Report on CASI
CASI Pharmaceuticals Stock Down 1.1 %
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last announced its quarterly earnings data on Friday, August 16th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. The company had revenue of $3.98 million during the quarter, compared to analysts’ expectations of $4.43 million. CASI Pharmaceuticals had a negative net margin of 118.81% and a negative return on equity of 126.20%.
Institutional Trading of CASI Pharmaceuticals
An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC lifted its holdings in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) by 10.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,800 shares of the biotechnology company’s stock after purchasing an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned about 0.30% of CASI Pharmaceuticals worth $224,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.23% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Read More
- Five stocks we like better than CASI Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best Aerospace Stocks Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.